FINWIRES · TerminalLIVE
FINWIRES

HKG:2142

13 stories mentioning HKG:2142Updated just now

Every FINWIRES story that references HKG:2142, newest first.

What's the latest news on HKG:2142?

Asia

HBM Unit Develops Language Model Trained on Fully Human Heavy-Chain-Only Antibodies

HBM Holdings (HKG:2142) unit Nona Biosciences developed HCAbLM, a language model trained on fully human heavy-chain-only antibodies (HCAbs).The model, the first of its kind globally, is designed to capture the unique sequence characteristics of fully human HCAbs, according to the report.The study, entitled "A foundation model learns the sequence and functional grammar of fully human heavy-chain-only antibodies," was published on bioRxiv.

HKG:2142
Asia

HBM Holdings Partner Solstice Oncology Raises $225 Million in Series A

HBM Holdings (HKG:2142) said its partner Solstice Oncology launched a $225 million Series A financing round led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors, according to a Wednesday Hong Kong bourse filing.Solstice is advancing porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, in two cancer indications, including microsatellite-stable stage 2-3 colon cancer, the filing said.

HKG:2142
Asia

HBM Partner Reports Positive Interim Results in Phase 2 Trial of Asthma Treatment

HBM Holdings' (HKG:2142) partner, Windward Bio AG, has reported positive interim results from the Phase 2 POLARIS-1 trial evaluating the company's treatment for asthma, according to a Tuesday bourse filing.The biopharmaceutical company said subjects responded well to its treatment, HBM9378/WIN378, during the trial conducted by Windward Bio, and observed no serious adverse events.HBM's partner has kicked off the Phase 3 trial and is also planning a second Phase 3 study, POLARIS-2, in the first half of next year.The company's shares were up 3% in early open-market trading in Hong Kong.

HKG:2142
Asia

HBM Holdings Enters Shanghai-, Shenzhen-Hong Kong Stock Connects

HBM Holdings' (HKG:2142) shares have been included as eligible stocks under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, according to a Monday bourse filing with the Hong Kong bourse.Qualified investors in mainland China can now directly invest in the company's shares through these Stock Connect programs.Shares of the biopharmaceutical company fell 1% in recent trade.

HKG:2142
Asia

HBM Holdings to Join Hang Seng Composite Index

HBM Holdings (HKG:2142) will be added to the Hang Seng Composite Index from Sept. 7, according to a Monday Hong Kong bourse filing.Its shares are also expected to meet the criteria to be traded through the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect.

HKG:2142
Asia

HBM's Cancer Drug Candidate Gets China Approval

HBM Holdings (HKG:2142) said China's National Medical Products Administration approved the investigational new drug application for HBM7004, a bispecific antibody candidate for advanced solid tumors.The approval follows U.S. clearance in May to begin a Phase I trial, allowing the company to advance clinical development in both markets, according to a Tuesday Hong Kong bourse filing.

HKG:2142
Asia

Hong Kong Stocks Fall on Friday Amid Rising Geopolitical Risks; MOG Digitech Jumps 13%

Hong Kong stocks closed lower on Friday as escalating tensions in the Middle East and fresh U.S. tariff measures weighed on investor sentiment.The Hang Seng Index fell 247.58 points, or 1%, to close at 24,963.23, while the Hang Seng China Enterprises Index lost 81.61 points, or also 1%, to 8,271.06.Investor sentiment weakened as the conflict in the Gulf kept oil prices volatile this month, raising concerns that higher energy costs could fuel inflation and keep interest rates elevated.Markets also reacted to President Donald Trump's announcement of tariffs ranging from 10% to 12.5% on dozens of countries, including the European Union.In corporate developments, MOG Digitech Holdings (HKG:1942) surged more than 13% despite forecasting a first-half net loss attributable to shareholders, compared with a profit a year earlier.HBM Holdings (HKG:2142) gained more than 1% after projecting a first-half profit of up to HK$67 million.

Hang SengHKG:1942HKG:2142
Asia

HBM Holdings Expects H1 Profit of Up to $67 Million

HBM Holdings (HKG:2142) expects to post a profit of $62 million to $67 million for the first half of 2026, according to a Friday Hong Kong bourse filing.The company expects first-half revenue to increase to $120 million to $125 million from $101 million a year earlier.HBM attributed the expected growth to continued tie-ups with multinational pharmaceutical companies, including its long-term partnership with AstraZeneca and global collaboration with Bristol Myers Squibb.

HKG:2142
Asia

HBM Holdings's Asthma Drug Candidate Secures China's Approval

HBM Holdings (HKG:2142) investigational new drug application for HBM7575, a long-acting bispecific antibody for asthma treatment, has been approved by China's National Medical Products Administration.HBM7575/SKB575, co-developed with Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990), targets thymic stromal lymphopoietin and an undisclosed target to treat asthma, according to a Wednesday Hong Kong bourse filing.Shares of the company rose over 1% in recent trade.

HKG:2142HKG:6990
Asia

HBM Holdings Unit Wins US Patent Verdict Against Amgen

HBM Holdings (HKG:2142) said a U.S. jury found in favor of its unit Harbour Antibodies in a patent infringement lawsuit against Amgen and its subsidiary Teneobio, according to a Monday Hong Kong bourse filing.The jury in the U.S. District Court for the District of Delaware found that Amgen infringed a patent covering Harbour Antibodies' antibody discovery platform, that the infringement was willful, and that the patent is valid.The jury awarded Harbour Antibodies damages of about $20.2 million, representing the full amount sought at trial.HBM said the finding of willful infringement allows Harbour Antibodies to seek enhanced damages, which could raise the award to as much as $60.6 million if granted in full by the court.

HKG:2142
Asia

HBM Holdings Partner Doses First Patient in SKB378 COPD Study

HBM Holdings (HKG:2142) said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.

HKG:2142
Asia

HBM Holdings' Obesity Drug Found to Have Favorable Profile in Preclinical Data

HBM Holdings (HKG:2142) said its LET003 drug candidate was found to have a more favorable drug-profile in the body than several competing molecules, according to a Monday filing with the Hong Kong bourse.According to preclinical data, the drug significantly enhanced fat reduction and preserved lean mass when combined with Novo Nordisk's weight loss drug semaglutide.Specifically, in an obesity model using wild-type mice, the drug combo decreased fat mass by 76% compared with 34.7% for semaglutide alone.The AI-enabled drug also promoted lean mass at lower doses, with effects comparable to those seen with higher doses of Novartis' bimagrumab, the firm said.

HKG:2142
Asia

HBM's Anti-Tumor Drug Application Gets FDA Clearance for Phase 1 Trial

HBM Holdings' (HKG:2142) investigational new drug application for a phase 1 trial of HBM7004 was cleared by the U.S. Food and Drug Administration (FDA), according to a Friday Hong Kong bourse filing.The drug was developed using the firm's HBICE platform to provide a differentiated approach to cancer immunotherapy.The trial aims to study the safety, tolerability, pharmacokinetics, and anti-tumor activity of the drug in patients with advanced solid tumors.

HKG:2142

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:2142 in your portfolio
WheelAI
WheelAI
Analyze HKG:2142 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:2142